660395-39-1

Basic information

• Product Name: 2-Morpholin-4-ylethylazide
• Synonyms: 2-Morpholin-4-ylethylazide;2-Morpholin-4-ylethylazide 98%;4-(2-Azidoethyl)morpholine
• CAS NO: 660395-39-1
• Molecular Formula: C₆H₁₂N₄O
• Molecular Weight: 156.18568
• Mol File: 660395-39-1.mol
• Article Data: 21

Chemical Properties

• Boiling Point: 74-76
• Appearance: /
• CAS DataBase Reference: 2-Morpholin-4-ylethylazide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Morpholin-4-ylethylazide(660395-39-1)
• EPA Substance Registry System: 2-Morpholin-4-ylethylazide(660395-39-1)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 660395-39-1(Hazardous Substances Data)

Usage

General Description

2-Morpholin-4-ylethylazide is a chemical compound with the formula C6H13N3O. It is a colorless liquid that is used as a reagent in organic synthesis and in the pharmaceutical industry. 2-Morpholin-4-ylethylazide is most commonly used as a precursor in the synthesis of various organic compounds, and it has also been studied for its potential applications in medicinal chemistry. Its azide functional group makes it useful in click chemistry reactions, which are widely used in chemical biology and materials science. Additionally, 2-Morpholin-4-ylethylazide is known for its ability to participate in a wide range of chemical reactions, making it a versatile and valuable tool in the field of synthetic chemistry.

InChI:InChI=1/C6H12N4O/c7-9-8-1-2-10-3-5-11-6-4-10/h1-6H2

Upstream product

• 622-40-2 2-(morpholin-4-yl)ethanol 
• 46230-78-8 2-(morpholin-1-yl)ethyl methanesulfonate 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 110-91-8 morpholine 
• 113738-22-0 tosylethylazide 
• 75178-70-0 2-azido-O-methanesulphonyl-ethanol 
• 89583-07-3 N-(2-bromoethyl)morpholine 
• 2038-03-1 4-(2-AMINOETHYL)MORPHOLINE 
• 3240-94-6 N-(2-chlorethyl)morpholine 
• 540-51-2 2-bromoethanol 

Downstream Products

• 910461-39-1 (E)-N-(tetrahydro-pyran-2-yloxy)-3-(1-{4-[1-(2-morpholin-4-yl-ethyl)-1H-[1,2,3]triazol-4-yl]-benzenesulfonyl}-1H-pyrrol-3-yl)-acrylamide 
• 1355046-40-0 C₁₆H₂₁N₅O₂ 
• 1316652-29-5 C₁₅H₁₉N₅O₃ 
• 1323917-28-7 2-(5-chloro-2-fluoro-phenyl)-4-{5-[1-(2-morpholin-4-yl-ethyl)-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-[1,8]naphthyridine 
• 1430724-35-8 N-(3-(5-(1-(2-morpholinoethyl)-1H-1,2,3-triazol-4-yl)-1H-benzo[d]imidazol-1-yl)-5-(1H-pyrrol-1-yl)phenyl)acetamide 
• 1431700-91-2 C₂₈H₃₃N₇O₃ 
• 1602731-57-6 C₂₁H₂₄N₆O₂ 
• 1602732-81-9 C₂₁H₂₄N₆O₂ 
• 1612887-60-1 C₆₀H₉₃N₅O₁₄ 
• 1622093-67-7 4-(2-(4-((4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)ethyl)morpholine 
• 2038-03-1 4-(2-AMINOETHYL)MORPHOLINE 

Relevant articles and documents

Lipid compound and composition thereof

The invention relates to a lipid compound and a composition thereof, a lipid nanoparticle containing the composition, a preparation method of the composition and application of the composition in drug delivery.

Facile Conversion of Molecularly Complex (Hetero)aryl Carboxylic Acids into Alkynes for Accelerated SAR Exploration

1,2,3-Triazoles are well-established bioisosteres for amides, often installed as a result of structure?activity-relationship (SAR) exploration. A straightforward approach to assess the effect of the replacement of an amide by a triazole would start from the carboxylic acid and the amine used for the formation of a given amide and convert them into the corresponding alkyne and azide for cyclization by copper-catalyzed alkyne?azide cycloaddition (CuAAC). Herein, we report a functional-group-tolerant and operationally simple decarbonylative alkynylation that allows the conversion of complex (hetero)aryl carboxylic acids into alkynes. Furthermore, the utility of this method was demonstrated in the preparation of a triazolo analog of the commercial drug moclobemide. Lastly, mechanistic investigations using labeled carboxylic acid derivatives clearly show the decarbonylative nature of this transformation.

COMPOUNDS AND METHODS FOR TREATING CANCER

Substituted cinnamamide compounds and analogs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or ameliorate cancer are provided.